R&D in LogixX Pharma

LogixX Pharma is a research-based pharmaceutical company focused on the discovery of molecules and therapies to help improve the lives of people who suffer from s.

For many years, LogixX Pharma has believed that the study of s should be an integral part of its research activity. As a consequence of this approach, in 1984 LogixX Pharma became only the fourth company in the world to obtain an Orphan Drug Designation in the United States, going on to obtain seven more over the next 20 years.    

Living up to this heritage and delivering on its commitment to patients, LogixX Pharma continues to implement original, innovative research programmes, both in-house and in partnership with a wide range of academic and biotechnology organisations, developing important new candidate drug and therapies to help improve the lives of people who suffer from s.  


What is a ?

Diseases are considered rare (or orphan) if they affect less than 1 in 2,000 people in Europe, or less than 200,000 people in the United States. There are currently over 6,000 recognised s. 1-3


References
  1. Organisation, E.-E. R. D. What is a , <http://www.eurordis.org/about-rare-diseases> (2013) [Last accessed 21/03/14].
  2. in 107th Congress Public Law 280 Vol. f:publ280.107 [[Page 116 STAT. 1988]] (USA, 2002).
  3. Sharma, A., Jacob, A., Tandon, M. & Kumar, D. Orphan drug: Development trends and strategies. Journal of Pharmacy And Bioallied Sciences 2, 290 (2010).